

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1-34 (Cancelled).

35. (Currently Amended) A method of treating a ~~disease or disorder~~ condition associated with *Streptococcus agalactiae* infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an isolated ~~peptide~~ polypeptide, which comprises an amino acid sequence of SEQ ID NO: 13.

36-37. (Canceled)

38. (Currently Amended) The method of claim 35, wherein said ~~peptide~~ polypeptide is encoded by a polynucleotide ~~comprising~~ set forth as SEQ ID NO: 12.

39. (Currently Amended) The method of claim 35, wherein said ~~peptide~~ polypeptide further comprising a heterologous peptide.

40. (Currently Amended) The method of claim 39, wherein said heterologous ~~peptide~~ polypeptide is a His tag.

41. (Previously Presented) The method of claim 35, wherein said composition further comprises a carrier.

42. (Previously Presented) The method of claim 41, wherein said composition further comprises an adjuvant.

43. (Previously Presented) The method of claim 42, wherein said adjuvant is alum.

44. (Previously Presented) The method of claim 35, wherein said subject is an animal.

45. (Previously Presented) The method of claim 44, wherein said animal is a human or a cow.

46. (Previously Presented) The method of claim 35, wherein said composition elicits an immune response.

47. (Currently Amended) The method of claim 35, wherein said ~~disease or disorder~~ condition is selected from the group consisting of: a Group B *Streptococcus* infection, septicaemia, pneumonia, osteomyelitis, septic arthritis, abscesses, endophthalmitis endophthalmitis, urinary ~~track~~ tract infection, and chronic mastitis.

48-50. (Canceled)

51. (Currently Amended) A method of inducing an immune response in a subject comprising administering to a subject in need thereof an effective amount of a composition comprising an isolated ~~peptide~~ polypeptide, which comprises SEQ ID NO: 13.

52. (Currently Amended) The method of claim 51, wherein said ~~peptide~~ polypeptide is encoded by a polynucleotide ~~comprising~~ set forth as SEQ ID NO: 12.

53. (Currently Amended) The method of claim 51, wherein said ~~peptide~~ polypeptide further comprising a heterologous peptide.

54. (Currently Amended) The method of claim 53, wherein said heterologous ~~peptide~~ polypeptide is a His tag.

55. (Previously Presented) The method of claim 53, wherein said composition further comprises a carrier.

56. (Previously Presented) The method of claim 55, wherein said composition further comprises an adjuvant.
57. (Previously Presented) The method of claim 56, wherein said adjuvant is alum.
58. (Previously Presented) The method of claim 51, wherein said subject is an animal.
59. (Previously Presented) The method of claim 58, wherein said animal is a human or a cow.